Valentina I. Petkov

Valentina I. Petkov

Auto-generated profile, based on publicly available information

Valentina I. Petkov

National Cancer Institute 17 Surveillance Research Program, Division of Cancer Control and Population Sciences Bethesda, Maryland

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2023 in JCO Precision Oncology
Verified
Journal Article
Open access
CBChristine N. Bailey
Christine N. Bailey
BMBrian Martin
Brian Martin
VPValentina I. Petkov
Valentina I. Petkov
NSNicola C. Schussler
Nicola C. Schussler
JSJennifer L. Stevens
Jennifer L. Stevens
SKSarah J. Kurley
Sarah J. Kurley
PURPOSE: The DecisionDx-Melanoma 31-gene expression profile (31-GEP) test is validated to classify cutaneous malignant melanoma (CM) patient risk of recurrence, metastasis, or death as low (class 1A), intermediate (class 1B/2A), or high (class 2B). This study aimed to examine the effect of 31-GEP testing on survival outcomes and confirm the prognostic ability of the 31-GEP at the population level. METHODS: Patients with stage I-III CM with a clinical 31-GEP result between 2016 and 2018 were linked to data from 17 SEER registries (n = 4,687) following registries' operation procedures for linkages. Melanoma-specific survival (MSS) and overall survival (OS) differences by 31-GEP risk category were examined using Kaplan-Meier analysis and the log-rank test. Crude and adjusted hazard ratios (HRs) were calculated using Cox regression model to evaluate variables associated with survival. 31-GEP tested patients were propensity score–matched to a cohort of non–31-GEP tested patients from the SEER database. Robustness of the effect of 31-GEP testing was assessed using resampling. RESULTS: Patients with a 31-GEP class 1A result had higher 3-year MSS and OS than patients with a class 1B/2A or class 2B result (MSS: 99.7% v 97.1% v 89.6%, P < .001; OS: 96.6% v 90.2% v 79.4%, P < .001). A class 2B result was an independent predictor of MSS (HR, 7.00; 95% CI, 2.70 to 18.00) and OS (HR, 2.39; 95% CI, 1.54 to 3.70). 31-GEP testing was associated with a 29% lower MSS mortality (HR, 0.71; 95% CI, 0.53 to 0.94) and 17% lower overall mortality (HR, 0.83; 95% CI, 0.70 to 0.99) relative to untested patients. CONCLUSION: In a population-based, clinically tested melanoma cohort, the 31-GEP stratified patients by their risk of dying from melanoma.

1 August 2024 in JNCI Monographs
Verified
Journal Article
Open access
PDF file
VPValentina I Petkov
Valentina I Petkov
JBJung S Byun
Jung S Byun
KWKevin C Ward
Kevin C Ward
NSNicola C Schussler
Nicola C Schussler
NANatalie P Archer
Natalie P Archer
LPLynne Penberthy
Lynne Penberthy
Background: Precision medicine has become a mainstay of cancer care in recent years. The National Cancer Institute (NCI) Surveillance, Epidemiology, and End Results (SEER) Program has been an authoritative source of cancer statistics and data since 1973. However, tumor genomic information has not been adequately captured in the cancer surveillance data, which impedes population-based research on molecular subtypes. To address this, the SEER Program has developed and implemented a centralized process to link SEER registries’ tumor cases with genomic test results that are provided by molecular laboratories to the registries. Methods: Data linkages were carried out following operating procedures for centralized linkages established by the SEER Program. The linkages used Match*Pro, a probabilistic linkage software, and were facilitated by the registries’ trusted third party (an honest broker). The SEER registries provide to NCI limited datasets that undergo preliminary evaluation prior to their release to the research community. Results: Recently conducted genomic linkages included OncotypeDX Breast Recurrence Score, OncotypeDX Breast Ductal Carcinoma in Situ, OncotypeDX Genomic Prostate Score, Decipher Prostate Genomic Classifier, DecisionDX Uveal Melanoma, DecisionDX Preferentially Expressed Antigen in Melanoma, DecisionDX Melanoma, and germline tests results in Georgia and California SEER registries. Conclusions: The linkages of cancer cases from SEER registries with genomic test results obtained from molecular laboratories offer an effective approach for data collection in cancer surveillance. By providing de-identified data to the research community, the NCI’s SEER Program enables scientists to investigate numerous research inquiries.

20 May 2017 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
DMDave P. Miller
Dave P. Miller
VPValentina I. Petkov
Valentina I. Petkov
SSSteven Shak
Steven Shak
537 Background: The Recurrence Score (RS) was shown in NSABP B-20 to predict chemotherapy (CT) benefit for RS ≥31 and no CT benefit for RS <18. The TAILORx results for RS <11 (NEJM 2015) reported excellent outcomes with no opportunity for CT to add additional benefit. As we await TAILORx results for RS 11-25, we characterized BC specific mortality (BCSM) for RS groups (cutoffs of 11, 18, 25, and 31) in the population-based SEER study of pts treated based on RS. Methods: RS results were provided to SEER registries per their methods (npj Breast Cancer 2016). Pts diagnosed (Jan 2004 - Dec 2012) with N0 HR+ HER2- negative BC, and no prior malignancy were eligible. BCSM estimates by CT use were computed using standard cutpoints of 18 and 31 and TAILORx cutpoints of 11 and 25. Results: Among 49,681 with a RS, 9,486 (19%) had RS <11, 17,988 (36%) had RS 11-17, 14,541 (29%) had RS 18-25, 3,805 (8%) had RS 26-30, and 3,861 (8%) had RS ≥31. Reported CT use and 5-y BCSM increased with increasing RS. For pts with both RS <11 and RS 11-17, CT use was uncommon and 5-y BCSM was low regardless of CT use. For pts with RS 18-25, CT use was more common and the 5-y BCSM was about 1% regardless of CT use. For pts with RS of 26-30 or ≥31, CT was common, and lower 5-y BCSM was observed with CT reported yes than with CT reported no or unknown. Conclusions: Pts in real-world clinical practice with RS <11, consistent with TAILORx, and pts with RS 11-17 have low 5-y BCSM with limited CT use, supporting hormonal therapy alone for pts with RS <18. The high end of the TAILORx mid-range (18-25) also showed good 5-y BCSM both with and without CT, highlighting the importance of the randomized results of TAILORx.

27 October 2025 in Journal of the American Medical Informatics Association
Verified
Journal Article
Closed access
MKMurat Kantarcioglu
Murat Kantarcioglu
WHWill Howe
Will Howe
BLBenmei Liu
Benmei Liu
VPValentina Petkov
Valentina Petkov
ECEsmeralda Casas-Silva
Esmeralda Casas-Silva
LPLynne Penberthy
Lynne Penberthy
Objective: The National Cancer Institute (NCI), part of the National Institutes of Health (NIH) supports efforts to address critical challenges in advancing cancer research. As part of this effort, NCI sponsored the development of a privacy-preserving record linkage (PPRL) software that transforms identifying patient information into multiple tokens through a set of cryptographically secure keyed hash functions. This project aims to evaluate the PPRL software in the perspective of re-identification risks and propose effective strategies to sufficiently mitigate these risks. Materials and Methods: To achieve the goals, we developed a novel re-identification risk assessment framework, based on token frequency analysis, to estimate the privacy impact of hashed tokens shared for record linkage. We assessed privacy risk through empirical analysis on a state-level voter registration database, a public dataset commonly used for re-identification, under various scenarios. These scenarios are defined based on several factors, including the size of the dataset used for linkage and a group size parameter that determines when an adversary can claim that a record has been re-identified. Results: We found that the re-identification risk based on frequency analysis attack is approximately 0.0002 (ie, 2 patients out of 10 000 are potentially identifiable) under reasonable adversarial settings, with a group size parameter of k = 12 and a dataset size of 400 000 patients. Additionally, our analysis reveals a negative correlation between dataset size and re-identification risk. Discussion: Re-identification risk is deemed low for the new NCI PPRL software. Token frequency analysis provides a reliable estimate of the re-identification risk in token-based PPRL tools.

1 September 2026 in Cancer Research Communications
Verified
Journal Article
Open access
JHJennifer N. Hoppe
Jennifer N. Hoppe
JLJocelyn Lee
Jocelyn Lee
TATomi Akinyemiju
Tomi Akinyemiju
DBDanielle S. Bitterman
Danielle S. Bitterman
MBMichael Brudno
Michael Brudno
JWJeremy L. Warner
Jeremy L. Warner
Adequately powered analyses in precision oncology often require combining cohorts across institutions. However, integration is constrained by the least granular source and may become infeasible when data elements are too heterogeneous to harmonize and map to a common data model. This challenge is acute in multi-institutional precision oncology research, in which real-world evidence requires harmonized clinico-omic data integration. Existing models often lack sufficient treatment patterns, outcomes, and genomic data, limiting interoperability and scalability. To address these gaps, American Association for Cancer Research Project Genomics Evidence Neoplasia Information Exchange (GENIE) developed the GENIE Data Model (GDM), a comprehensive, open-source oncology data model for scalable, consistent, and interoperable data collection across solid tumors, designed to effectively capture the journey of patients with cancer. Through iterative consensus-building, four working groups comprising 13 subject matter experts defined data elements across multiple clinical domains: patient characteristics, imaging, diagnosis, surgery, histopathology, biomarkers, systemic therapy, radiation, clinical trial history, disease response and outcomes, and social determinants of health. Elements were defined using standardized terminologies and permissible values to support mapping to Health Level 7 Fast Healthcare Interoperability Resources, Observational Medical Outcomes Partnership, and other existing oncology standards. The model architecture distinguishes manually abstracted elements from computationally collected elements, enabling parallel workflows. The GDM provides an extensible framework that addresses critical gaps and enables scalable, harmonized data collection essential for precision oncology and real-world evidence generation. Significance: The GDM is an open-source, ready-to-implement, solid tumor framework that standardizes clinical and genomic data capture across institutions to effectively capture the journey of patients with cancer. It enables interoperable mapping to existing standards, accelerates multisite study start-up, and supports scalable real-world evidence generation in precision oncology.

23 September 2026
Verified
Other
Open access
JHJennifer N. Hoppe
Jennifer N. Hoppe
JLJocelyn Lee
Jocelyn Lee
TATomi Akinyemiju
Tomi Akinyemiju
DBDanielle S. Bitterman
Danielle S. Bitterman
MBMichael Brudno
Michael Brudno
JWJeremy L. Warner
Jeremy L. Warner
GDM domain schema. The GDM schema summarizes the full set of data elements collected to represent the journey of a person living with cancer by integrating (i) foundational structured data encoded in routine clinical systems using standard terminologies (Fig. 2), (ii) high-value variables that often require manual abstraction from unstructured documentation, and (iii) derived variables calculated from (i) and (ii). The schema organizes elements into domains centered on the patient with cancer. The person-centered domain includes demographics, geographical linkage to area SDoH, individual-level SDoH (education, employment, marital status), hospitalization events, comorbidities, vital signs/performance status, and laboratory testing. The treatment-centered domain includes surgeries (procedures and pathology reports) and radiotherapy (course/phase, technique/modality, and dosimetry), systemic therapies (drug-level exposure with start/end dates and modification/discontinuation reasons), and clinical trial participation. The diagnosis-centered domain includes cancer diagnosis (ICD-O-3 tumor classification coding; diagnostic confirmation framework), cancer staging [grade, behavior, morphology, tumor–node–metastasis (TNM)], and genomic profiling of tumors (somatic alterations and sequencing panel metadata). Lastly, the outcomes-centered domain includes imaging (event dates, imaging types, radiologist assessment of cancer status and response) and clinical visits (event dates, visit types, and oncologist assessment of cancer status and response). The outcomes-centered domain also harmonizes temporally anchored tumor-centric assessments and person-centric measures to compute real-world endpoints, including overall survival (OS), progression-free survival (PFS), time to treatment discontinuation (TTD), time to next treatment (TTNT), and real-world response rate (rwRR). Together, these domains represent the complete GDM scope and illustrate how combining coded structured data with curated abstraction enables robust longitudinal phenotyping for real-world evidence generation. AE, adverse event; CNS, central nervous system; CTCAE, Common Terminology Criteria for Adverse Events; DOB, Date of Birth; ECOG, Eastern Cooperative Oncology Group; EOD, extent of disease; KPS, Karnofsky performance status; LTFU, Lost to Follow-Up; MGMT, O6-methylguanine-DNA methyltransferase; NDI, National Death Index; SDV, Source Data Verification; SSDI, Site-Specific Data Item. (Icon in this figure adapted from an image generated by ChatGPT, February 6, 2026, OpenAI, https://chat.openai.com.)